Seeyond reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,971 shares of the life sciences company’s stock after selling 51 shares during the quarter. Seeyond’s holdings in Illumina were worth $2,352,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently bought and sold shares of ILMN. Evermay Wealth Management LLC purchased a new stake in Illumina during the second quarter valued at about $26,000. Eagle Bay Advisors LLC purchased a new stake in shares of Illumina in the second quarter worth about $35,000. BDO Wealth Advisors LLC boosted its position in shares of Illumina by 90.5% in the first quarter. BDO Wealth Advisors LLC now owns 80 shares of the life sciences company’s stock worth $31,000 after buying an additional 38 shares during the period. Tsfg LLC boosted its position in shares of Illumina by 1,580.0% in the second quarter. Tsfg LLC now owns 84 shares of the life sciences company’s stock worth $40,000 after buying an additional 79 shares during the period. Finally, Evoke Wealth LLC boosted its position in shares of Illumina by 165.6% in the first quarter. Evoke Wealth LLC now owns 85 shares of the life sciences company’s stock worth $33,000 after buying an additional 53 shares during the period. 88.56% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts recently commented on ILMN shares. Robert W. Baird reissued a “hold” rating on shares of Illumina in a report on Sunday, August 22nd. SVB Leerink downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 price target for the company. in a report on Thursday, August 19th. Barclays upped their price objective on Illumina from $355.00 to $365.00 and gave the company an “underweight” rating in a research note on Friday, August 6th. TheStreet cut Illumina from a “b-” rating to a “c” rating in a research note on Wednesday, October 6th. Finally, Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $504.00 price objective on the stock in a research note on Wednesday, June 30th. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus target price of $432.83.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, August 5th. The life sciences company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.51. Illumina had a return on equity of 18.12% and a net margin of 19.36%. The business had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the firm earned $0.62 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 6.48 earnings per share for the current year.
In related news, SVP Susan H. Tousi sold 300 shares of the stock in a transaction that occurred on Wednesday, July 28th. The stock was sold at an average price of $486.41, for a total value of $145,923.00. Following the completion of the transaction, the senior vice president now directly owns 42,743 shares of the company’s stock, valued at approximately $20,790,622.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Susan H. Tousi sold 100 shares of the stock in a transaction on Tuesday, September 28th. The shares were sold at an average price of $418.04, for a total value of $41,804.00. The disclosure for this sale can be found here. Insiders sold a total of 2,642 shares of company stock valued at $1,268,895 over the last three months. Corporate insiders own 0.23% of the company’s stock.
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.
Featured Story: What are Bollinger Bands?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.